Pharmacodynamics of cisatracurium in the intensive care unit: an observational study

Eric Dieye, Vincent Minville, Karim Asehnoune, Claude Conil, Bernard Georges, Pierre Cougot, Olivier Fourcade, Jean-Marie Conil, Eric Dieye, Vincent Minville, Karim Asehnoune, Claude Conil, Bernard Georges, Pierre Cougot, Olivier Fourcade, Jean-Marie Conil

Abstract

Background: Data from previous studies indicate that optimal conditions for intubation are met 120 seconds after administration of 0.15 mg.kg-1 cisatracurium (ED95 × 3) following the induction of anesthesia. The aim of this study was to compare the doses required for complete paralysis after induction of anesthesia in ICU patients with the dose used in patients undergoing elective surgery.

Methods: Seventeen ICU patients undergoing percutaneous tracheostomy and 17 patients undergoing an elective surgical procedure under muscle relaxation were included. In both groups, an initial intravenous bolus of cisatracurium besylate was given at a dose of 0.15 mg.kg-1 followed by repeated boluses of 0.03 mg.kg-1 every four minutes. The objective was to obtain no response to the train-of-four (TOF). The contractile response of the corrugator supercilii muscle was monitored every minute by observing the TOF in response to a peripheral nerve stimulator with a constant current set to 60 mA.

Results: After the initial dose of cisatracurium, none of ICU patients (0/17) versus 15/17 of the elective surgery patients were completely paralyzed (P < 0.0001). There was a delay in the onset of neuromuscular blockade among the ICU patients. The cumulative doses of cisatracurium were significantly higher in the ICU group with 38 ± 14 mg (that is, 10 ± 4.7 ED95) versus 11 ± 2 mg (that is, 3 ± 0.3 ED95) in the elective surgery group (P < 0.0001).

Conclusion: The dosing of cisatracrurium for ICU patients, which is based on the dose recommended for elective anesthesia, is unsuitable because the onset is too slow. This phenomenon is probably caused by changes in the pharmacodynamics and pharmacokinetics. These data suggest that neuromuscular monitoring should be used in the ICU.

Figures

Figure 1
Figure 1
Time of neuromuscular blockade for ICU (1) and surgical patients (0). * = P < 0.05 using the Mann–Whitney U-test.
Figure 2
Figure 2
Cumulative doses of cisatracurium for ICU (1) and surgical patients (0). * = P < 0.05 using the Mann–Whitney U-test.

References

    1. Papazian L, Forel J-M, Gacouin A, Penot-Ragon C, Perrin G, Loundou A, Jaber S, Arnal J-M, Perez D, Seghboyan J-M, Constantin J-M, Courant P, Lefrant J-Y, Guérin C, Prat G, Morange S, Roch A. ACURASYS Study Investigators. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med. 2010;4:1107–1116. doi: 10.1056/NEJMoa1005372.
    1. Boyd AH, Eastwood NB, Parker CJ, Hunter JM. Pharmacodynamics of the 1R cis-1′R cis isomer of atracurium (51 W89) in health and chronic renal failure. Br J Anaesth. 1995;4:400–404. doi: 10.1093/bja/74.4.400.
    1. De Wolf AM, Freeman JA, Scott VL, Tullock W, Smith DA, Kisor DF, Kerls S, Cook DR. Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation. Br J Anaesth. 1996;4:624–628. doi: 10.1093/bja/76.5.624.
    1. Lien CA, Schmith VD, Belmont MR, Abalos A, Kisor DF, Savarese JJ. Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. Anesthesiology. 1996;4:300–308. doi: 10.1097/00000542-199602000-00007.
    1. Eastwood NB, Boyd AH, Parker CJ, Hunter JM. Pharmacokinetics of 1R-cis 1′R-cis atracurium besylate (51 W89) and plasma laudanosine concentrations in health and chronic renal failure. Br J Anaesth. 1995;4:431–435. doi: 10.1093/bja/75.4.431.
    1. Klessig HT, Geiger HJ, Murray MJ, Coursin DB. A national survey on the practice patterns of anesthesiologist intensivists in the use of muscle relaxants. Crit Care Med. 1992;4:1341–1345. doi: 10.1097/00003246-199209000-00024.
    1. Sharpe MD. The use of muscle relaxants in the intensive care unit. Can J Anaesth. 1992;4:949–962. doi: 10.1007/BF03008345.
    1. Meistelman C, Plaud B. Neuromuscular blockade: is it still useful in the ICU? Eur J Anaesthesiol Suppl. 1997;4:53–56.
    1. Sapirstein A, Hurford WE. Neuromuscular blocking agents in the management of respiratory failure. Indications and treatment guidelines. Crit Care Clin. 1994;4:831–843.
    1. Shapiro BA, Warren J, Egol AB, Greenbaum DM, Jacobi J, Nasraway SA, Schein RM, Spevetz A, Stone JR. Practice parameters for sustained neuromuscular blockade in the adult critically ill patient: an executive summary. Society of critical care medicine. Crit Care Med. 1995;4:1601–1605. doi: 10.1097/00003246-199509000-00022.
    1. Miller RD. Use of neuromuscular blocking drugs in intensive care unit patients. Anesth Analg. 1995;4:1–2.
    1. Belmont MR, Lien CA, Quessy S, Abou-Donia MM, Abalos A, Eppich L, Savarese JJ. The clinical neuromuscular pharmacology of 51 W89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia. Anesthesiology. 1995;4:1139–1145. doi: 10.1097/00000542-199505000-00008.
    1. Lepage JY, Malinovsky JM, Malinge M, Lechevalier T, Dupuch C, Cozian A, Pinaud M, Souron R. Pharmacodynamic dose–response and safety study of cisatracurium (51 W89) in adult surgical patients during N2O-O2-opioid anesthesia. Anesth Analg. 1996;4:823–829.
    1. Bluestein LS, Stinson LW, Lennon RL, Quessy SN, Wilson RM. Evaluation of cisatracurium, a new neuromuscular blocking agent, for tracheal intubation. Can J Anaesth. 1996;4:925–931. doi: 10.1007/BF03011806.
    1. Littlejohn IH, Abhay K, Sayedel A, Broomhead CJ, Duvaldestin P, Flynn PJ. Intubating conditions following 1R CIS, 1′R CIS atracurium (51W89). A comparison with atracurium. Anaesthesia. 1995;4:499–502. doi: 10.1111/j.1365-2044.1995.tb06038.x.
    1. Beemer GH, Bjorksten AR. Pharmacodynamics of atracurium in clinical practice: effect of plasma potassium, patient demographics, and concurrent medication. Anesth Analg. 1993;4:1288–1295. doi: 10.1213/00000539-199306000-00018.
    1. Waud BE, Waud DR. Interaction of calcium and potassium with neuromuscular blocking agents. Br J Anaesth. 1980;4:863–866. doi: 10.1093/bja/52.9.863.
    1. Vanderheyden BA, Reynolds HN, Gerold KB, Emanuele T. Prolonged paralysis after long-term vecuronium infusion. Crit Care Med. 1992;4:304–307. doi: 10.1097/00003246-199202000-00019.
    1. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med. 1999;4:461–470. doi: 10.7326/0003-4819-130-6-199903160-00002.
    1. Melloni C, Devivo P, Launo C, Mastronardi P, Novelli GP, Romano E. Cisatracurium versus vecuronium: a comparative, double blind, randomized, multicenter study in adult patients under propofol/fentanyl/N2O anesthesia. Minerva Anestesiol. 2006;4:299–308.
    1. Boyd AH, Eastwood NB, Parker CJ, Hunter JM. Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cis-atracurium (51 W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit. Br J Anaesth. 1996;4:382–388. doi: 10.1093/bja/76.3.382.
    1. Prielipp RC, Coursin DB, Scuderi PE, Bowton DL, Ford SR, Cardenas VJ, Vender J, Howard D, Casale EJ, Murray MJ. Comparison of the infusion requirements and recovery profiles of vecuronium and cisatracurium 51 W89 in intensive care unit patients. Anesth Analg. 1995;4:3–12.
    1. Mellinghoff H, Radbruch L, Diefenbach C, Buzello W. A comparison of cisatracurium and atracurium: onset of neuromuscular block after bolus injection and recovery after subsequent infusion. Anesth Analg. 1996;4:1072–1075.
    1. Martyn JA, White DA, Gronert GA, Jaffe RS, Ward JM. Up-and-down regulation of skeletal muscle acetylcholine receptors. Effects on neuromuscular blockers. Anesthesiology. 1992;4:822–843. doi: 10.1097/00000542-199205000-00022.
    1. Hogue CW, Ward JM, Itani MS, Martyn JA. Tolerance and upregulation of acetylcholine receptors follow chronic infusion of d-tubocurarine. J Appl Physiol. 1992;4:1326–1331.
    1. Danon MJ, Carpenter S. Myopathy with thick filament (myosin) loss following prolonged paralysis with vecuronium during steroid treatment. Muscle Nerve. 1991;4:1131–1139. doi: 10.1002/mus.880141115.
    1. Ibebunjo C, Nosek MT, Itani MS, Martyn JA. Mechanisms for the paradoxical resistance to d-tubocurarine during immobilization-induced muscle atrophy. J Pharmacol Exp Ther. 1997;4:443–451.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する